Product Overview

Alternative Name: NSP-989; NSP-989 COMBO; Tanaproget COMBO; WAY-166989

Development Status: Active Development

Target: Female

Mode: Hormonal

Delivery Type: Oral

Duration Type: Short-acting

Description: Tanaproget (NSP-989) is a novel, non-steroidal, high affinity, high efficacy, and very selective progesterone receptor agonist. Due to its much more selective binding profile relative to most conventional, steroidal progestins, tanaproget may prove to produce fewer side effects in comparison.

Updated date: June 06, 2016

Vertical Tabs


Project Phase: Late Development

Project Stage: Phase II

Began discovery in: Prior to 2005

Status Details:
  • Sublicensed to Pfizer in 2010.

Download Product Report